Umecrine AB’s business concept is to develop antagonists to CNS-active steroids (GABA-A modulating steroid antagonists, GAMSA) to reduce symptoms and conditions caused by endogenous sex and stress hormones on the brain. This is a unique and novel treatment principle based on antagonizing the action of GABA-A receptor modulating steroids.

The company strategy is to bring componds into development and then out-license, or seek a strategic partnership or an M&A transaction with a company searching for a new opportunity within the field of CNS or Women’s Health.